Semaglutide Explained: What It Is, How It Works, and Who It's For

Semaglutide has become one of the most discussed drugs in medicine — but public coverage often focuses on demand and shortages rather than the underlying science. This guide covers what semaglutide actually is, how it works at a molecular level, and what the clinical trials demonstrate.

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist — a synthetic molecule that binds to and activates the same receptors as the body's naturally occurring glucagon-like peptide-1 (GLP-1). It was developed by Novo Nordisk and structurally modified from native GLP-1 to extend its half-life from a few minutes to approximately one week, enabling once-weekly dosing.

The modification involves attaching a fatty acid chain to the molecule, which allows it to bind reversibly to albumin in the blood — delaying renal clearance and protecting it from enzymatic degradation by DPP-4.

Approved uses and brand names

Semaglutide is approved under three brand names in the US:

• Ozempic (injectable, 0.5–2mg weekly) — approved for type 2 diabetes management and cardiovascular risk reduction
• Wegovy (injectable, up to 2.4mg weekly) — approved for chronic weight management in adults with obesity or overweight plus a weight-related comorbidity
• Rybelsus (oral tablet, 7–14mg daily) — approved for type 2 diabetes; oral bioavailability is approximately 1% of the injectable

The distinction between Ozempic and Wegovy is primarily one of indication and dose — both contain semaglutide. See our guide on semaglutide brand names for more detail.

How it works

Semaglutide acts on GLP-1 receptors throughout the body. In the pancreas, it stimulates insulin secretion in a glucose-dependent manner (meaning it doesn't cause hypoglycemia when blood sugar is normal). In the gut, it slows gastric emptying. In the brain — specifically the hypothalamus and brainstem — it reduces hunger signaling and increases satiety perception.

This central appetite effect is a major driver of weight loss. For a detailed look at how GLP-1 affects appetite through both peripheral and central pathways, see our full breakdown.

What the STEP trials showed

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program is the largest body of evidence for semaglutide in weight management. Key findings:

• STEP 1: Adults with obesity (no diabetes) lost an average of 14.9% of body weight over 68 weeks on 2.4mg semaglutide vs. 2.4% on placebo
• STEP 2: Adults with type 2 diabetes lost an average of 9.6% on 2.4mg vs. 3.4% on placebo
• STEP 5: Two-year data showed maintained weight loss of ~15%, demonstrating durability of effect with continued treatment

See How Much Weight Can You Lose on Semaglutide for a full breakdown of the trial data with confidence intervals and responder analysis.

Who is semaglutide appropriate for?

For weight management (Wegovy), FDA approval covers adults with a BMI ≥30, or ≥27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). Prescribing decisions require evaluation by a licensed clinician. For the dosing schedule used in clinical practice, see Semaglutide Dosing Schedule.

Semaglutide doesn't create willpower — it changes the hormonal environment in which appetite decisions are made.